Vulnerability in Hospira Symbiq Infusion System
CVE-2015-3965
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
Published · last modified .
CVSS v3 metric
CVSS v3 base score 8.8 (High). Vector: CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H.
EPSS exploit prediction
EPSS: 0.029 (86.3th percentile), scored .
Low probability of exploitation in the next 30 days, but still tracked. 86th percentile — 86.3% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.
EPSS over last 30 days · oldest: 0.029 · newest: 0.029 · change: 0.000
Affected products
- Hospira Symbiq Infusion System — versions 3.13 and earlier
- Pfizer Symbiq Infusion System
- Pfizer Symbiq Infusion System Firmware
Weakness classification (CWE)
References
- ics-cert.us-cert.gov/advisories/ICSA-15-174-01 (US Government Resource, Third Party Advisory)
Frequently asked questions
- What is CVE-2015-3965?
- CVE-2015-3965 is a high-severity vulnerability in Hospira Symbiq Infusion System, classified under CWE-264. CVSS score: 8.8/10. Published 2019-03-23.
- How severe is CVE-2015-3965?
- High severity. CVSS v3 base score is 8.8 out of 10.